Ramy Ibrahim, M.D., Parker Institute for Cancer Immunotherapy, explains that the study Focuses on Frontline Metastatic Pancreatic Cancer | Patients Get Added Benefits of Investigational Agents.
Focuses on Frontline Metastatic Pancreatic Cancer | Patients Get Added Benefits of Investigational Agents
